

# Daniel Shasha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9478391/publications.pdf>

Version: 2024-02-01

44  
papers

1,816  
citations

566801

15  
h-index

454577

30  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1808  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. <i>Journal of Urology</i> , 2003, 169, 2008-2012.	0.2	625
2	Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes. <i>Oncologist</i> , 2002, 7, 492-508.	1.9	320
3	Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment. <i>Oncology</i> , 2005, 68, 3-11.	0.9	156
4	Radiotherapy-Associated Anemia: The Scope of the Problem. <i>Oncologist</i> , 2000, 5, 1-7.	1.9	109
5	The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 1033-1043.	0.4	102
6	Once-weekly dosing of epoetin-? increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. <i>Cancer</i> , 2003, 98, 1072-1079.	2.0	98
7	Prophylactic Sildenafil Citrate Improves Select Aspects of Sexual Function in Men Treated with Radiotherapy for Prostate Cancer. <i>Journal of Urology</i> , 2014, 192, 868-874.	0.2	70
8	Prevalence of Anemia in Cancer Patients Undergoing Radiotherapy: Prognostic Significance and Treatment. <i>Oncology</i> , 2002, 63, 11-18.	0.9	49
9	Thermoluminescent dosimetry of the Symmetraâ„¢ 125I model I25.S06 interstitial brachytherapy seed. <i>Medical Physics</i> , 2001, 28, 1761-1769.	1.6	45
10	Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. <i>Supportive Care in Cancer</i> , 2004, 12, 268-273.	1.0	44
11	The negative impact of anemia on radiotherapy and chemoradiation outcomes. <i>Seminars in Hematology</i> , 2001, 38, 8-15.	1.8	32
12	The negative impact of anemia on radiotherapy and chemoradiation outcomes. <i>Seminars in Hematology</i> , 2001, 38, 8-15.	1.8	24
13	ELECTIVE IRRADIATION OF THE NO NECK IN SQUAMOUS CELL CARCINOMA OF THE UPPER AERODIGESTIVE TRACT. <i>Otolaryngologic Clinics of North America</i> , 1998, 31, 803-813.	0.5	21
14	Standard of Care for Cancer-Related Anemia: Improving Hemoglobin Levels and Quality of Life. <i>Oncology</i> , 2005, 68, 22-32.	0.9	19
15	The role of brachytherapy in head and neck cancer. <i>Seminars in Radiation Oncology</i> , 1998, 8, 270-281.	1.0	15
16	Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy. <i>Oral Oncology</i> , 2013, 49, 956-963.	0.8	14
17	Contemporary management of localized penile cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 29-36.	1.1	13
18	Relationship Between Hemoglobin Levels and Quality of Life During Radiation Therapy Plus Concomitant or Sequential Chemotherapy in Patients With Cancer and Anemia Treated With Epoetin Alfa. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2, 509-517.	2.3	12

#	ARTICLE	IF	CITATIONS
19	Exploration of the Role of Radiotherapy in the Management of Early Glottic Cancer with Complete Carotid Artery Occlusion. <i>Onkologie</i> , 2013, 36, 3-3.	1.1	9
20	Radiotherapy-Associated Anemia: The Scope of the Problem. <i>Oncologist</i> , 2000, 5, 1-7.	1.9	9
21	The role of brachytherapy for palliation. <i>Seminars in Radiation Oncology</i> , 2000, 10, 222-239.	1.0	7
22	Prevalence of anemia in cancer patients undergoing radiation therapy. <i>Seminars in Oncology</i> , 2001, 28, 54-59.	0.8	6
23	Sildenafil Citrate and Risk of Biochemical Recurrence in Prostate Cancer Patients Treated with Radiation Therapy: Post-Hoc Analysis of a Randomized Controlled Trial. <i>Journal of Sexual Medicine</i> , 2021, 18, 1467-1472.	0.3	4
24	Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer. <i>Brachytherapy</i> , 2021, 20, 1099-1106.	0.2	3
25	Hematopoietic Response to Extended Dosing of Epoetin alfa 60,000 U Every 2 Weeks in Anemic Cancer Patients Not Receiving Therapy: Final Results.. <i>Blood</i> , 2005, 106, 3764-3764.	0.6	3
26	An Internet-ready database for prospective randomized clinical trials of high-dose-rate brachytherapy for adenocarcinoma of the prostate. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 104-115.	0.4	2
27	Management algorithm for HIV-associated parotid lymphoepithelial cysts. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 3355-3362.	0.8	2
28	BRACHYTHERAPY IN THE TREATMENT OF COLORECTAL MALIGNANCIES. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 559-575.	0.9	1
29	Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity. <i>BJU International</i> , 2021, , .	1.3	1
30	Weekly epoetin alfa treatment of anemia in patients with cancer not undergoing therapy. <i>The Journal of Supportive Oncology</i> , 2006, 4, 129-35.	2.3	1
31	15. Dosimetric Coverage Achieved with 125 Permanent Prostate Brachytherapy Often Exceeds Pathologic Estimates of Extraprostatic Tumor Extension. <i>Cancer Journal (Sudbury, Mass )</i> , 2003, 9, 488.	1.0	0
32	A comparison of post-implant day 0 vs. day 30 dosimetry for LDR interstitial transperineal prostate brachytherapy. <i>Brachytherapy</i> , 2008, 7, 180.	0.2	0
33	A Comparison of Post-Implant Day 0 vs Day 30 “ Dosimetry for Low-Dose-Rate Interstitial Prostate Brachytherapy. <i>Brachytherapy</i> , 2010, 9, S74.	0.2	0
34	Is Low-Dose-Rate Interstitial Brachytherapy for Patients with Large Prostates (>60 cc) Safe and Effective?. <i>Brachytherapy</i> , 2010, 9, S99.	0.2	0
35	1959 SIGNIFICANT AGE DEPENDENCE OF TESTOSTERONE RECOVERY AFTER ANDROGEN DEPRIVATION (ADT) IN PROSTATE CANCER PATIENTS TREATED WITH CURATIVE RADIATION. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
36	Biochemical Outcomes in Patients with Gleason Score 9 or 10 Adenocarcinoma of the Prostate from a Single Institution. <i>Brachytherapy</i> , 2013, 12, S65.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Biochemical Outcomes in Patients with Gleason Score 8 Adenocarcinoma of the Prostate from a Single Institution. <i>Brachytherapy</i> , 2013, 12, S69.	0.2	0
38	Oncologic and Toxicity Outcomes after Prostate Brachytherapy for HIV-Positive Patients. <i>Brachytherapy</i> , 2014, 13, S40-S41.	0.2	0
39	Prostate Cancer Dose Escalation via Simultaneous Integrated Brachytherapy Boost Delivered via Radioactive I125 vs. Pd103 Seeds Followed by External Beam Radiation Therapy. <i>Brachytherapy</i> , 2014, 13, S118-S119.	0.2	0
40	Adequate Geographic Coverage of Microscopic Extracapsular Tumor Extension Is Usually Achieved with Permanent Pd-103 Prostate Brachytherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 519.	1.0	0
41	Epoetin alfa 80,000 U Every Three Weeks (Q3W) in Anemic Cancer Patients (pts) Not Receiving Chemotherapy (CT) or Radiation Therapy (RT).. <i>Blood</i> , 2006, 108, 3755-3755.	0.6	0
42	Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.. <i>Blood</i> , 2007, 110, 3775-3775.	0.6	0
43	PSA outcomes in patients with adenocarcinoma of the prostate with presenting PSA > 20 ng/ml.. <i>Journal of Clinical Oncology</i> , 2013, 31, 241-241.	0.8	0
44	Biochemical and functional outcomes of brachytherapy for young men (â%50) with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 245-245.	0.8	0